Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

This study has been completed.
Sponsor:
Collaborators:
Gateway for Cancer Research
University of Southern California
Information provided by (Responsible Party):
Weili Sun, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier:
NCT01861002
First received: May 21, 2013
Last updated: July 29, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)